- Company
- Patients and policy are trending in the pharma industry
- by Eo, Yun-Ho Apr 6, 2023 05:53am
- The opening of new positions that didn’t exist before indicates the considerable need for the positions. Recently, Korean subsidiaries of multinational pharmaceutical companies that mainly supply new drugs have opened up two new positions - GA (Government Affairs) and PA (Patient Advocacy). The changes seem to be in line with the trend
- Policy
- Government's drug pricing policy
- by Lee, Jeong-Hwan Apr 5, 2023 05:48am
- The Ministry of Health and Welfare revealed its will to create a specific preferential drug price policy for innovative new drugs and essential drugs, and at the same time, it revealed a policy to use generic drugs by reducing drug prices, attracting attention. Recently, in the process of reviewing the amendment to the Special Act on the Pro
- Policy
- Countdown to initial non-face-to-face treatment
- by Lee, Jeong-Hwan Apr 5, 2023 05:48am
- The Power of the People Together with Rep. Kim Seong-won, Democratic Party Rep. Kang Hoon-sik co-represented the National Assembly's startup research group'Unicorn Farm', which plans to propose a bill to amend the Medical Act to allow non-face-to-face treatment from the first visit on the 3rd. The representative initiative of the bill is Kim
- Product
- Prescription of flu Txs rise with the spread of influenza A
- by Kang, Hye-Kyung Apr 5, 2023 05:48am
- Pharmacies are busy dispensing treatments due to the resurgence of influenza A, which has become prevalent again after December last year. Although a flu outbreak in March, the start of the new school year, is common, due to the lifting of the mask-wearing regulation and the varying temperature in the spring season, the adeno, rhino, paraviru
- Product
- No. of Paxlovid prescriptions drop at pharmacies
- by Jung, Heung-Jun Apr 5, 2023 05:47am
- Contrary to the government’s plans to expand the number of pharmacies in charge of COVID-19 treatments to 6,000, the number has not increased from 4,000 due to reduced prescriptions. Moreover, pharmacies handling the COVID-19 treatments are predicting that more pharmacies would be applying to cancel their designation from the second half
- Company
- Active M&A for global cell and gene therapy
- by Hwang, Jin-joon Apr 5, 2023 05:47am
- In the field of cell and gene therapy, which is considered a next-generation drug, an M&A worth 3.4 trillion won was completed. Domestic biopharmaceutical companies are conducting R&D in the field of cell and gene therapy as a future food source. CDMO companies are entering the CDMO business for cell and gene therapy through M&A and factory e
- Company
- Celltrion discloses interim results of global phase 3 Eylea
- by Hwang, Jin-joon Apr 5, 2023 05:45am
- On the 3rd, Celltrion disclosed the interim results based on the 24th week of the global phase 3 clinical trial of CT-P42, an eye disease treatment Eylea biosimilar. Celltrion is conducting clinical trials for 52 weeks on 348 DME patients in 13 countries, including Germany and Spain. The interim results released this time are the results of c
- Company
- CHMP gave a positive opinion on the approval of Soliris
- by Jung, Sae-Im Apr 5, 2023 05:44am
- On the 31st of last month, Samsung Bioepis announced that it had obtained a positive opinion for the item approval of 'EPYSQLITM (Eculizumab)', a treatment for rare diseases, from the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA). EPYSQLITM is a biosimilar of Alexion's paroxysmal nocturnal hem
- Company
- Hanmi internationally introduces 7 new drug candidates
- by Hwang, Jin-joon Apr 4, 2023 05:53am
- Hanmi Pharmaceutical is revealing its messenger ribonucleic acid (mRNA) cancer vaccine and new targeted anticancer lead compounds. The company reinforced its anticancer pipeline by adding next-generation anticancer drug technologies and targets to its existing major anticancer drug pipeline that has been making smooth progress in preclinical
- Company
- Medytox paid service fees of KRW 97.7B in 4 years
- by Kim, Jin-Gu Apr 4, 2023 05:52am
- The service fees paid out by Medytox during the past 4 years have reached nearly KRW 100 billion. Since 2019, disputes related to botulinum toxin had risen simultaneously in the United States and Korea, which led to an increase in the litigation costs and fees the company has spent. The amount of annual service fee payouts decreased afte
